Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001)

Rheumatology

Volumn 44, Issue 2, 2005, Pages 157-163

  Ledingham, J ^b   Deighton, Chris ^a,c  

^a DERBY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^c DERBYSHIRE ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; LIVE VACCINE; METHOTREXATE; PENICILLAMINE; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ARTICLE; AUTOIMMUNITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSULTATION; DEMYELINATION; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUSTRY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HEMATOLOGIC DISEASE; HEPATITIS C; HUMAN; INFECTION; LACTATION; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL SOCIETY; MEDICAL SPECIALIST; NEUROLOGIC DISEASE; NONHUMAN; PANCYTOPENIA; PRACTICE GUIDELINE; PREGNANCY; PRESCRIPTION; PRIMARY HEALTH CARE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SOLID TUMOR; STANDARDIZATION; SURGICAL TECHNIQUE; SYSTEMIC LUPUS ERYTHEMATOSUS; TERATOGENICITY; TREATMENT FAILURE; TUBERCULOSIS; VACCINATION; VIRUS REACTIVATION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOGLOBULIN G; PATIENT SELECTION; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 14044260093     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keh464     Document Type: Article

References (98)

1. British Society for Rheumatology. Guidelines for prescribing TNF-α blockers in adults with rheumatoid arthritis. London: British Society for Rheumatology, 2001 (www.rheumatology.org.uk).
2. Breedveld FC, Emery P, Keystone E et al. Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 2004;63:149-55.
3. Keystone EC, Haraoui B, Bykerk VP. Role of Infliximab in the treatment of early rheumatoid arthritis. Clin Exp, Rheumatol 2003;21(suppl 31):S200-S202.
4. Keystone EC, Haraoui B, Bykerk VP. Role of adalimumab in the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 2003;21(suppl 31):S198-S199.
5. Bathon JM, Genovese MC. The Early Rheumatoid Arthritis (ERA) trial comparing the efficacy and safety of etanercept and methotrexate. Clin Exp Rheumatol 2003;21(suppl 31):S195-S197.
6. Emery P, Seto Y. Role of biologics in early arthritis. Clin Exp Rheumatol 2003;21(suppl 31):S191-S194.
7. Markham A, Lamb HM. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 2000;59:1341-59.
8. Kavanaugh AF. Anti-tumor necrosis factor-alpha monoclonal antibody therapy for rheumatoid arthritis. Rheum Dis Clin North Am 1998;24:593-614.
9. Jones RE, Moreland LW. Tumor necrosis factor inhibitors for rheumatoid arthritis. Bull Rheum Dis 1999;48:1-4.
10. Harriman G, Harper LK, Schaible TF. Summary of clinical trials in rheumatoid arthritis using Infliximab, an anti-TNFalpha treatment. Ann Rheum Dis 1999;58(suppl 1):161-4.
11. Garrison L, McDonnell ND. Etanercept: therapeutic use in patients with rheumatoid arthritis. Ann Rheum Dis 1999;58(suppl 1):165-9.
12. Furst DE, Keystone E, Maini RN, Smolen JS. Recapitulation of the round-table discussion - assessing the role of anti-tumor necrosis factor therapy in the treatment of rheumatoid arthritis. Rheumatology 1999;38(suppl 2):50-3.
13. Elliott MJ, Maini RN, Feldmann M et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993;36:1681-90.
14. Elliott MJ, Maini RN, Feldmann M et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1125-7.
15. Bathon JM, Martin RW, Fleischmann RM et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
16. Lipsky PE, van der Heijde DM, St Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
17. Moreland LW, Schiff MH, Baumgartner SW et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-86.
18. Slifman NR, Gershon SK, Lee JH, Edwards ET, Braun MM. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum 2003;48:319-24.
19. De Rosa FG, Shaz D, Campagna AC, Dellaripa PE, Khettry U, Craven DE. Invasive pulmonary aspergillosis soon after therapy with Infliximab, a tumor necrosis factor-alpha-neutralizing antibody: a possible healthcare-associated case? Infect Control Hosp Epidemiol 2003;24:477-82.
20. Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology 2003;42:617-21.
21. Furst DE, Schiff MH, Fleischmann RM et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003;30:2563-71.
22. Hanauer SB. Review article: safety of Infliximab in clinical trials. Aliment Pharmacol Ther 1999;13(suppl 4):16-22.
23. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287-93.
24. Doran MR, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002;46:2294-300.
25. Cheifetz A, Smedley M, Martin S et al. The incidence and management of infusion reactions to Infliximab: a large center experience. Am J Gastroenterol 2003;98:1315-24.
26. Edwards KR, Mowad CM, Tyler WB. Worsening injection site reactions with continued use of etanercept. J Drugs Dermatol. 2003;2:184-7.
27. Weisman MH, Moreland LW, Furst DE et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther 2003;25:1700-21.
28. Jarvis B, Faulds D. Etanercept: a review of its use in rheumatoid arthritis. Drugs 1999;57:945-66.
29. Hochberg MC, Tracy JK, Hawkins-Holt M, Flores RH. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept and Infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 2003;62(suppl 2):ii13-ii16.
30. Flendrie M, Creemers MC, Welsing PM, den Broeder AA, van Riel PL. Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis 2003;62(suppl 2): ii30-ii33.
31. van Vollenhoven R, Harju A, Brannemark S, Klareskog L. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Ann Rheum Dis 2003;62:1195-8.
32. Ang HT, Helfgott S. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis? J Rheumatol 2003;30:2315-18.
33. Buch MH, Bingham SJ, Seto Y et al. Switching biologics after initial anti-tumour necrosis-a failure: success with further TNF-a antagonism but failure on subsequent interleukin-1 receptor antagonism. Rheumatology 2004; 43(suppl 2):37.
34. Bennett AN, Peterson P, Banya N et al. Adalimumab in clinical practice - initial experience at a single UK center. Rheumatology 2004;43(suppl 2):37.
35. Wick MC, Lindblad S, Klareskog L, Van Vollenhoven RF. Adalimumab restores clinical response in patients who have lost response to infliximab (Remicade) or Etanercept (Enbrel): Data from the STURE registry. Ann Rheum Dis 2004;63(suppl 1): 260.
36. Van der Bijl AE, Breedveld FC, Antoni C et al. Infliximab failures in rheumatoid arthritis can be successfully treated with Adalimumab (Humira). Ann Rheum Dis 2004;63(suppl 1):264.
37. Brocq O, Albert CC, Roux CH et al. Adalimumab in severe rheumatoid arthritis after failure of one or two anti-TNF: 18 patients. Ann Rheum Dis 2004;63(suppl 1):531.
38. Feltelius N, Fored M, Blomqvist P et al. Safety and efficacy of adalimumab in arthritis patients previously treated with another biologic agent. Ann Rheum Dis 2004;63(suppl 1):304.
39. Kiely PDW, Johnson DM. Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open label study. Rheumatology 2003;41:631-7.
40. Durez P, Nzeusseu A, Dufour JP, Derogelaer JP, Houssiau FA. Treatment of severe refractory Ra with a combination of infliximab and azathioprine: one year results of an open label pilot study. Ann Rheum Dis 2002;61:abstract FRI0140.
41. Weinblatt ME, Kremer JM, Bankhurst AD et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
42. Klareskog L, van der Heijde D, de Jager JP et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81.
43. Cohen JD, Zaltni S, Kaiser MJ et al. Secondary addition of methotrexate to partial responders to etanercept alone is effective in severe rheumatoid arthritis. Ann Rheum Dis 2004;63:209-10.
44. Weinblatt ME, Keystone EC, Furst DE et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45.
45. Moreland LW, Margolies G, Heck LW Jr et al. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol 1996;23:1849-55.
46. Sidiropoulos P, Bertsias G, Kritikos HD, Kouroumali H, Voudouris K, Boumpas DT. Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit. Ann Rheum Dis 2004;63:144-8.
47. Den Broeder AA, Creemers MC, van Gestel AM, van Riel PL. Dose titration using the Disease Activity Score (DAS28) in rheumatoid arthritis patients treated with anti-TNF-alpha. Rheumatology 2002;41:638-42.
48. De Rosa FG, Shaz D, Campagna AC, Dellaripa PE, Khettry U, Craven DE. Invasive pulmonary aspergillosis soon after therapy with Infliximab, a tumor necrosis factor-alpha-neutralizing antibody: a possible healthcare-associated case? Infect Control Hosp Epidemiol 2003;24:477-82.
49. Gottlieb GS, Lesser CF, Holmes KK, Wald A. Disseminated sporotrichosis associated with treatment with immunosuppressants and tumor necrosis factor-alpha antagonists. Clin Infect Dis 2003;37:838-40.
50. Bowie VL, Snella KA, Gopalachar AS, Bharadwaj P. Listeria meningitis associated with Infliximab. Ann Pharmacother 2004;38: 58-61.
51. Hage CA, Wood KL, Winer-Muram HT, Wilson SJ, Sarosi G, Knox KS. Pulmonary cryptococcosis after initiation of anti-tumor necrosis factor-alpha therapy. Chest 2003;124:2395-7.
52. Netea MG, Radstake T, Joosten LA, van der Meer JW, Barrera P, Kullberg BJ. Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression. Arthritis Rheum 2003;48:1853-7.
53. Cairns AP, Taggart AJ. Anti-tumour necrosis factor therapy for severe inflammatory arthritis: two years of experience in Northern Ireland. Ulster Med J 2002;71:101-5.
54. Gayliss N. Infliximab in the treatment of an HIV positive patient with Reiter's syndrome. J Rheumatol 2003;30:407-11.
55. Walker RE, Spooner KM, Kelly G. Inhibition of immunoreactive tumor necrosis factor-α by a chimeric antibody in patients infected with human immunodeficiency virus type 1. J Infect Dis 1996; 174: 63-8.
56. Mantry PS, De Cross AJ, Ryan CK, Berg MJ. An interesting case of Crohn's disease in a patient with HIV infection treated with REMICADE [abstract]. American College of Gastroenterology 66th Annual Scientific Meeting, Las Vegas, NV, October 22-24, 2001. Abstract P497.
57. Tessnow K, Chiao L, Jamjian C et al. Safety and efficacy of infliximab therapy in HIV patients with Crohn's disease. Digestive Disease Week, San Francisco, CA, May 19 22, 2002. Abstract 107000.
58. Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after Infliximab in a patient with hepatitis B virus treated for an adult onset Still's disease. J Rheumatol 2003;30:1624-5.
59. Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with Infliximab and low dose methotrexate. Ann Rheum Dis 2003;62:686-7.
60. Oniankitan O, Duvoux C, Challine D et al. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol 2004;31:107-9.
61. Peterson JR, Hsu FC, Simkin PA, Wener MH. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 2003;62:1078-82.
62. Khanna M, Shirodkar MA, Gottlieb AB. Etanercept therapy in patients with autoimmunity and hepatitis C. J Dermatol Treat 2003;14:229-32.
63. Pritchard C. Etanercept and hepatitis C. J Clin Rheumatol 1999;5:179-80.
64. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with Infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
65. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of Infliximab therapy. Arthritis Rheum 2004;50:372-9.
66. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003;48:2122-7.
67. Manadan AM, Block JA, Sequeiera W. Mycobacteria tuberculosis peritonitis associated with etanercept therapy. Clin Exp Rheumatol 2003;21:526.
68. Abbott Laboratories. Humira prescribing information. North Chicago, IL 600064, USA: Abbott Laboratories, December 2002.
69. British Thoracic Society. BTS recommendations for assessing risk, and for managing M. tuberculosis infection and disease in patients due to start anti-TNF-α treatment. London: British Thoracic Society, 2004 (www.brit-thoracic.org.uk). To be published in Thorax and Rheumatology.
70. Elkayam O, Caspi D, Reitblatt T, Charboneau D, Rubins JB. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 2004;33:283-8.
71. British Society for Rheumatology. Vaccinations in the immunocompromised person - guidelines for the patient taking immunosuppressants, steroids and the new biologic therapies. London: British Society for Rheumatology, 2002 (www.rheumatology.org.uk).
72. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002;46:3151-8.
73. Prior P, Symmons DP, Hawkins CF, Scott DL, Brown R. Cancer morbidity in rheumatoid arthritis. Ann Rheum Dis 1984;43:128-31.
74. Isomaki HA, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis 1978;31:691-6.
75. Baecklund E, Ekbom A, Sparen P, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. Br Med J 1998;317:180-1.
76. Baert F, Noman M, Vermeire S et al. Influence of immunogenicity on the long-term efficacy of Infliximab in Crohn's disease. N Engl J Med 2003;348:601-8.
77. Debandt M, Vittecoq O, Descamps V, Le Loet X, Meyer O. Anti-TNF-alpha-induced systemic lupus syndrome. Clin Rheumatol 2003;22:56-61.
78. De Rycke L, Kruithof F, Van Damme N et al. Antinuclear antibodies following Infliximab treatment in patients with rheumatoid arthritis or spondyloarthropathy. Arthritis Rheum 2003;48:1015-23.
79. Louis M, Rauch J, Armstrong M, Fitzcharles MA. Induction of autoantibodies during prolonged treatment with Infliximab. J Rheumatol 2003;30:2557-62.
80. Lepore L, Marchetti F, Facchini S, Leone V, Ventura A. Drug-induced systemic lupus erythematosus associated with etanercept therapy in a child with juvenile idiopathic arthritis. Clin Exp Rheumatol 2003;21:276-7.
81. Swale VJ, Perrett CM, Denton CP, Black CM, Rustin MH. Etanercept-induced systemic lupus erythematosus. Clin Exp Dermatol 2003;28:604-7.
82. Carlson E, Rothfield N. Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis. Arthritis Rheum 2003;48:1165-6.
83. Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003;138:807-11.
84. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT, Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of Infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003;107:3133-40.
85. Anker SD, Coats AJ. How to recover from renaissance? The significance of the results of recover, renaissance, renewal and ATTACH. Int J Cardiol 2002;86:123-30.
86. Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 2004;116:305-11.
87. Mohan N, Edwards ET, Cupps TR et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001;44:2862-9.
88. Sicotte NL, Voskuhl RR. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 2001;57:1885-8.
89. Robinson WH, Genovese MC, Moreland LW. Demyelinating and neurologic events reported in association with tumor necrosis factor α antagonism. Arthritis Rheum 2001;44:1977-83.
90. Vidal F, Fontova R, Richart C. Severe neutropenia and thrombocytopenia associated with Infliximab. Ann Intern Med 2003;139:63.
91. Aouba A, De Bandt M, Aslangul E, Atkhen N, Patri B. Haemophagocytic syndrome in a rheumatoid arthritis patient treated with Infliximab. Rheumatology 2003;42:800-2.
92. Alcain G, Andrade RJ, Queipo de Llano MP, Moreno MJ, Garcia-Corte M, Franquelo E. Acute leukemia after Infliximab therapy. Am J Gastroenterol 2003;98:2577.
93. Baklane G, Nossent H. Acute myelogenous leukaemia following etanercept therapy. Rheumatology 2003;42:900-1.
94. Maini RN, Breedveld FC, Kalden JR et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41: 1552-63.
95. Kuruvilla J, Leitch HA, Vickars LM et al. Aplastic, anemia following administration of a tumor necrosis factor-alpha inhibitor. Eur J Haematol 2003;71:396-8.
96. Ferrero S, Ragni N. Inflammatory bowel disease: management issues during pregnancy. Arch Gynecol Obstet 2004;270:79-85 (Epub 2003 30 April).
97. Burt MJ, Frizelle FA, Barbezat GO. Pregnancy and exposure to Infliximab (anti-tumor necrosis factor-alpha monoclonal antibody). J Gastroenterol Hepatol 2003;18:465-6.
98. Chakravarty EF, Sanchez-Yamamoto D, Bush TM. The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes. J Rheumatol 2003;30:241-6.